Literature DB >> 8082709

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.

D Quartermain1, J Mower, M F Rafferty, R L Herting, T H Lanthorn.   

Abstract

The memory-enhancing potential of D-cycloserine (cycloserine) a partial agonist at the glycine recognition site on the NMDA receptor, was evaluated in mice using a thirst-motivated linear maze learning task. Immediate acute post-training injections (10, 20 and 80 mg/kg) significantly improved retention relative to vehicle-injected controls. Retention was also facilitated if cycloserine (3 and 10 mg/kg but not 20 or 40 mg/kg) was administered 20 min before the retention test. Acquisition of the habit was accelerated if cycloserine (3 mg/kg) was injected 20 min before the training session. Acute post-training injections failed to facilitate retention if mice were pretreated with cycloserine (3 mg/kg) b.i.d. for 15 days before training on the maze. These results indicate that acute cycloserine administration can enhance consolidation and retrieval of memory but that desensitization may occur with chronic exposure to the drug.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082709     DOI: 10.1016/0014-2999(94)90687-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  67 in total

Review 1.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

Review 2.  Behavioral and neurobiological mechanisms of extinction in Pavlovian and instrumental learning.

Authors:  Travis P Todd; Drina Vurbic; Mark E Bouton
Journal:  Neurobiol Learn Mem       Date:  2013-08-30       Impact factor: 2.877

Review 3.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

Authors:  Stefan G Hofmann; Mark H Pollack; Michael W Otto
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 4.  Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy.

Authors:  Michael Davis; Karyn M Myers; Jasmeer Chhatwal; Kerry J Ressler
Journal:  NeuroRx       Date:  2006-01

5.  Effects of the novel NMDA-receptor antagonist SDZ EAA 494 on memory and attention in humans.

Authors:  S Rockstroh; M Emre; A Tarral; R Pokorny
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

6.  Augmentation of exposure therapy with post-session administration of D-cycloserine.

Authors:  Candyce D Tart; Pamela R Handelsman; Lindsey B Deboer; David Rosenfield; Mark H Pollack; Stefan G Hofmann; Mark B Powers; Michael W Otto; Jasper A J Smits
Journal:  J Psychiatr Res       Date:  2012-10-23       Impact factor: 4.791

7.  D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

Authors:  JoAnn Difede; Judith Cukor; Katarzyna Wyka; Megan Olden; Hunter Hoffman; Francis S Lee; Margaret Altemus
Journal:  Neuropsychopharmacology       Date:  2013-11-12       Impact factor: 7.853

8.  Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice.

Authors:  Peter A Groblewski; K Matthew Lattal; Christopher L Cunningham
Journal:  Alcohol Clin Exp Res       Date:  2009-03-06       Impact factor: 3.455

9.  D-cycloserine and cocaine cue reactivity: preliminary findings.

Authors:  Kimber L Price; Aimee L McRae-Clark; Michael E Saladin; Megan M Moran-Santa Maria; Stacia M DeSantis; Sudie E Back; Kathleen T Brady
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

10.  Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease.

Authors:  Hirosha Geekiyanage; Aditi Upadhye; Christina Chan
Journal:  Neurobiol Aging       Date:  2013-03-23       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.